SI1910370T1 - Piridin kinolin substituirani pirolo(1,2-b)pirazol monohidrat kot tgf-beta inhibitor - Google Patents

Piridin kinolin substituirani pirolo(1,2-b)pirazol monohidrat kot tgf-beta inhibitor

Info

Publication number
SI1910370T1
SI1910370T1 SI200631924T SI200631924T SI1910370T1 SI 1910370 T1 SI1910370 T1 SI 1910370T1 SI 200631924 T SI200631924 T SI 200631924T SI 200631924 T SI200631924 T SI 200631924T SI 1910370 T1 SI1910370 T1 SI 1910370T1
Authority
SI
Slovenia
Prior art keywords
tgf
pyridin
beta inhibitor
substituted pyrrolo
pyrazole monohydrate
Prior art date
Application number
SI200631924T
Other languages
English (en)
Slovenian (sl)
Inventor
Sreenivasa Reddy Mundla
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI1910370T1 publication Critical patent/SI1910370T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200631924T 2005-07-22 2006-06-29 Piridin kinolin substituirani pirolo(1,2-b)pirazol monohidrat kot tgf-beta inhibitor SI1910370T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70164105P 2005-07-22 2005-07-22
PCT/US2006/025377 WO2007018818A1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
EP20060774280 EP1910370B1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor

Publications (1)

Publication Number Publication Date
SI1910370T1 true SI1910370T1 (sl) 2015-06-30

Family

ID=37450942

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631924T SI1910370T1 (sl) 2005-07-22 2006-06-29 Piridin kinolin substituirani pirolo(1,2-b)pirazol monohidrat kot tgf-beta inhibitor

Country Status (16)

Country Link
US (1) US7872020B2 (enExample)
EP (1) EP1910370B1 (enExample)
JP (1) JP5242391B2 (enExample)
BR (1) BRPI0613639A2 (enExample)
CA (1) CA2616196C (enExample)
DK (1) DK1910370T3 (enExample)
ES (1) ES2542425T3 (enExample)
HR (1) HRP20150474T1 (enExample)
HU (1) HUE025209T2 (enExample)
IL (1) IL188181A (enExample)
MX (1) MX2008001020A (enExample)
PL (1) PL1910370T3 (enExample)
PT (1) PT1910370E (enExample)
RS (1) RS53999B1 (enExample)
SI (1) SI1910370T1 (enExample)
WO (1) WO2007018818A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
MX369576B (es) * 2011-07-13 2019-11-13 Tiumbio Co Ltd Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4.
ES2791627T3 (es) 2012-11-12 2020-11-05 Inst Catalana Recerca Estudis Avancats Métodos y kits para el pronóstico del cáncer colorrectal
CA2905842C (en) 2013-03-14 2023-02-21 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US10822337B2 (en) 2015-04-01 2020-11-03 Rigel Pharmaceuticals, Inc. TGF-β inhibitorC
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3390406A1 (en) 2015-12-15 2018-10-24 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN109548403A (zh) * 2016-07-07 2019-03-29 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
JP2019534266A (ja) 2016-10-14 2019-11-28 江蘇恒瑞医薬股▲ふん▼有限公司 5員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
WO2018165979A1 (zh) * 2017-03-17 2018-09-20 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
US10995083B2 (en) 2017-03-21 2021-05-04 Hangzhou Solipharma Co., Ltd. Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
EP3768267B1 (en) 2018-03-20 2025-05-14 Icahn School of Medicine at Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2022515652A (ja) 2018-12-31 2022-02-21 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
CN115282280A (zh) * 2022-08-12 2022-11-04 中国科学技术大学 TGF-β1信号抑制剂的新用途
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100861630B1 (ko) 2001-05-24 2008-10-07 일라이 릴리 앤드 캄파니 제약 제제로서의 신규 피롤 유도체
CA2506799A1 (en) * 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles

Also Published As

Publication number Publication date
CA2616196A1 (en) 2007-02-15
CA2616196C (en) 2012-08-21
MX2008001020A (es) 2008-03-25
IL188181A0 (en) 2008-03-20
HRP20150474T1 (xx) 2015-06-05
US7872020B2 (en) 2011-01-18
IL188181A (en) 2014-05-28
PL1910370T3 (pl) 2015-09-30
BRPI0613639A2 (pt) 2012-02-22
US20100120854A1 (en) 2010-05-13
JP2009502780A (ja) 2009-01-29
ES2542425T3 (es) 2015-08-05
EP1910370B1 (en) 2015-04-22
PT1910370E (pt) 2015-06-30
DK1910370T3 (en) 2015-06-08
WO2007018818A1 (en) 2007-02-15
JP5242391B2 (ja) 2013-07-24
RS53999B1 (sr) 2015-10-30
HUE025209T2 (en) 2016-03-29
EP1910370A1 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
SI1910370T1 (sl) Piridin kinolin substituirani pirolo(1,2-b)pirazol monohidrat kot tgf-beta inhibitor
IL184717A0 (en) Imidazo (1,2-a)pyridine compounds as vegf-r2 inhibitors
SI1697356T1 (sl) Pirido(2,3-d)pirimidin-2,4-diamini kot zaviralci PDE 2
SI1966202T1 (sl) S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
SI1893612T1 (sl) Pirolo b piridin derivati kot protein kinazni inhibitorji
EG25765A (en) Pyrido [2,3-B] pyrazine derivatives useful as herbicidal compounds
PL1711481T5 (pl) Krystaliczny monohydrat jako inhibitor kinazy
IL197393A0 (en) Pyridin-4-yl derivatives as immunomodulating agents
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200904440B (en) 6-Benzyl-2,3,4,7-Tetrahydro-indolo [2,3-C] quinoline compounds useful as PDE5 inhibitors
IL190456A0 (en) Pyrazolo[4,3-d]pirimidin-5-yl)derivative used as pde5 inhibitors
ZA200804104B (en) Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
ZA200709919B (en) Pyrrol (2,3-B) pyridine derivatives protein kinase inhibitors
IL178774A0 (en) Imidazopyridine compound
IS8553A (is) Pýrasól(3,4-b) pýridin efnasamband, og notkun þess sem PDE 4 hindri
HK1099769A (en) Imidazopyridine compound
CY1116567T1 (el) ΕΝΑ ΠΥΡΙΔΙΝΟΚΙΝΟΛΙΝΟ-ΥΠΟΚΑΣΤΕΣΤΗΜΕΝΟ ΜΟΝΟΕΝΥΔΡΟ ΠΥΡΡΟΛΟ [1,2-B]ΠΥΡΑΖΟΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΤΟΥ TGF-β
HK1138515A (en) Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
HK1102588A (en) Tetrahydro-imidazo (1,5-a) pyridin derivatives as aldosterone synthase inhibitors
HK1103085A (en) Pyrimidinylpyrazoles as tgf-beta inhibitors
HK1103042A (en) Pyrimidinylimidazoles as tgf-beta inhibitors